Literature DB >> 1621218

Immunosuppression in patients with Barrett's esophagus.

M Oka1, S E Attwood, B Kaul, T C Smyrk, T R DeMeester.   

Abstract

BACKGROUND: Patients with Barrett's esophagus have a higher incidence of esophageal cancer than has the general population. Local tissue injury and exposure to carcinogens presumably play a role in malignant transformation, but the possibility of altered host immune surveillance must also be considered.
METHODS: The level of immunoreactivity was investigated in six healthy control subjects; 14 patients with gastroesophageal reflux, seven with and seven without esophagitis; and nine patients with Barrett's esophagus. Parameters studied were (1) T-cell and B-cell function with mitogen-stimulated lymphocyte blastogenesis, (2) immunosuppressive properties of autologous serum, and (3) interleukin-2 production by peripheral blood mononuclear cells. Nutritional status as a possible cause for immunosuppression was assessed by measurement of serum albumin, transferrin, and prealbumin.
RESULTS: Patients with Barrett's esophagus had a significant suppression of all T-cell (p less than 0.01) and B-cell function (p less than 0.01) and interleukin-2 production (p less than 0.001) when they were compared to the controls. Interleukin-2 production was also reduced significantly compared to that in patients with gastroesophageal reflux with and without esophagitis (p less than 0.05). No differences were observed in serum immunosuppression or nutritional factors.
CONCLUSIONS: Although the immunosuppression observed in the patients with Barrett's esophagus was milder than that found in other immunocompromised states, it may be sufficient to encourage the malignant transformation of Barrett's mucosa.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1621218

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Gastroesophageal reflux disease after lung transplantation: pathophysiology and implications for treatment.

Authors:  Christopher S Davis; Vidya Shankaran; Elizabeth J Kovacs; James Gagermeier; Daniel Dilling; Charles G Alex; Robert B Love; James Sinacore; P Marco Fisichella
Journal:  Surgery       Date:  2010-08-21       Impact factor: 3.982

2.  Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers.

Authors:  G Morgan
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

3.  Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study.

Authors:  Vinicius J Campos; Guilherme S Mazzini; José F Juchem; Richard R Gurski
Journal:  J Gastrointest Surg       Date:  2019-11-19       Impact factor: 3.452

4.  NSAIDs and the chemoprevention of colon and oesophageal cancer.

Authors:  G P Morgan
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

5.  Gastritis in Barrett's esophagus.

Authors:  R J Mason; C G Bremner
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

Review 6.  Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis.

Authors:  Ashna Gupta; Ravi Chauhan; Tarang Sharma; Ajaz A Bhat; Sabah Nisar; Sheema Hashem; Sabah Akhtar; Aamir Ahmad; Mohammad Haris; Mayank Singh; Shahab Uddin
Journal:  Cancer Metastasis Rev       Date:  2022-05-05       Impact factor: 9.237

Review 7.  The 8th Wonder of the Cancer World: Esophageal Cancer and Inflammation.

Authors:  Harleen Kaur Chela; Karthik Gangu; Hamza Ertugrul; Alhareth Al Juboori; Ebubekir Daglilar; Veysel Tahan
Journal:  Diseases       Date:  2022-07-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.